

Kylie D Mason

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5381437/publications.pdf>

Version: 2024-02-01

41
papers

6,875
citations

361413

20
h-index

330143

37
g-index

41
all docs

41
docs citations

41
times ranked

9572
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer during pregnancy: A qualitative study of healthcare experiences of Australian women. <i>European Journal of Cancer Care</i> , 2021, 30, e13425.	1.5	7
2	Feasibility of Enhancing Parenting in Cancer, a Psychoeducational intervention for communicating with children about parental cancer. <i>Psycho-Oncology</i> , 2021, 30, 1172-1177.	2.3	6
3	Capturing the Lived Experiences of Women with Lymphoma in Pregnancy: An Australasian Lymphoma Alliance Study. <i>Blood</i> , 2021, 138, 4099-4099.	1.4	1
4	Lymphoma during Pregnancy: A Multicentre Study By the Australasian Lymphoma Alliance. <i>Blood</i> , 2021, 138, 882-882.	1.4	3
5	Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence. <i>Journal of Translational Medicine</i> , 2021, 19, 473.	4.4	11
6	Open-Label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2020, 61, 2103-2112.	1.3	55
7	Updated Analysis of an Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 14-15.	1.4	2
8	Maternal breast cancer and communicating with children: A qualitative exploration of what resources mothers want and what health professionals provide. <i>European Journal of Cancer Care</i> , 2019, 28, e13153.	1.5	19
9	Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. <i>Blood</i> , 2019, 133, 1964-1976.	1.4	104
10	Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study. <i>Lancet Oncology</i> , The, 2019, 20, 216-228.	10.7	163
11	Breaking Good – Improving Access to Primary Care Based Long Term Follow Up for Allograft Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S108.	2.0	0
12	Comparison of gene expression and flow cytometry for immune profiling in chronic lymphocytic leukaemia. <i>Journal of Immunological Methods</i> , 2018, 463, 97-104.	1.4	4
13	Open-Label, Phase 2 Study of Blinatumomab As Second Salvage Therapy in Adults with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 400-400.	1.4	11
14	Altered B-lymphopoiesis in mice with deregulated thrombopoietin signaling. <i>Scientific Reports</i> , 2017, 7, 14953.	3.3	4
15	Study protocol for Enhancing Parenting In Cancer (EPIC): development and evaluation of a brief psycho-educational intervention to support parents with cancer who have young children. <i>Pilot and Feasibility Studies</i> , 2017, 3, 72.	1.2	16
16	Diagnosis within a Diagnosis: An Unusual Case of Intracranial Hypertension. <i>Neuro-Ophthalmology & Visual Neuroscience</i> , 2017, 2, 1-3.	0.0	0
17	Nephrotic syndrome as a complication of chronic graft-versus-host disease after allogeneic haemopoietic stem cell transplantation. <i>Internal Medicine Journal</i> , 2016, 46, 737-741.	0.8	16
18	Eliminating Legionella by inhibiting BCL-XL to induce macrophage apoptosis. <i>Nature Microbiology</i> , 2016, 1, 15034.	13.3	75

#	ARTICLE	IF	CITATIONS
19	Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 3032-3032.	1.4	12
20	Phase 1b study of venetoclax plus R- or G-CHOP in patients with B-cell non-Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7566-7566.	1.6	5
21	Autoreactive T cells induce necrosis and not BCL-2-regulated or death receptor-mediated apoptosis or RIPK3-dependent necroptosis of transplanted islets in a mouse model of type 1 diabetes. <i>Diabetologia</i> , 2015, 58, 140-148.	6.3	32
22	Mitochondrial apoptosis is dispensable for <sc>NLRP</sc>3 inflammasome activation but nonâ€œapoptotic caspaseâ€œ is required for inflammasome priming. <i>EMBO Reports</i> , 2014, 15, 982-990.	4.5	189
23	Disseminated toxoplasmosis after allogeneic stem cell transplantation in a seronegative recipient. <i>Transplant Infectious Disease</i> , 2013, 15, E14-9.	1.7	18
24	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. <i>Nature Medicine</i> , 2013, 19, 202-208.	30.7	2,426
25	Marked eosinophilia with abnormal basophilic granules in acute graftâ€œversusâ€œhost disease postâ€œallogeneic haemopoietic stem cell transplant for acute myeloid leukaemia without <sc><i>CBFBâ€œMYH11</i></sc> mutation. <i>European Journal of Haematology</i> , 2013, 90, 175-176.	2.2	0
26	Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 2599-2604.	7.1	43
27	Low adhesion receptor levels on circulating platelets in patients with lymphoproliferative diseases before receiving Navitoclax (ABT-263). <i>Blood</i> , 2013, 121, 1479-1481.	1.4	20
28	HoxA9 regulated Bcl-2 expression mediates survival of myeloid progenitors and the severity of HoxA9-dependent leukemia. <i>Oncotarget</i> , 2013, 4, 1933-1947.	1.8	48
29	Pharmacological blockade of Bcl-2, Bcl-xL and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice. <i>Cell Death and Differentiation</i> , 2012, 19, 623-632.	11.2	17
30	Inhibitor of Apoptosis Proteins Limit RIP3 Kinase-Dependent Interleukin-1 Activation. <i>Immunity</i> , 2012, 36, 215-227.	14.3	430
31	Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. <i>Journal of Experimental Medicine</i> , 2011, 208, 2017-2031.	8.5	162
32	Bcl-xLâ€œinhibitory BH3 mimetics can induce a transient thrombocytopenia that undermines the hemostatic function of platelets. <i>Blood</i> , 2011, 118, 1663-1674.	1.4	262
33	Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. <i>Journal of Cell Biology</i> , 2011, 194, i12-i12.	5.2	0
34	BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 10967-10971.	7.1	97
35	The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. <i>Leukemia</i> , 2009, 23, 2034-2041.	7.2	91
36	Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. <i>Blood</i> , 2009, 114, 663-666.	1.4	274

#	ARTICLE	IF	CITATIONS
37	Go with the flow for monitoring response in myeloma with minimal residual disease. <i>Leukemia and Lymphoma</i> , 2008, 49, 177-178.	1.3	8
38	In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17961-17966.	7.1	137
39	Programmed Anuclear Cell Death Delimits Platelet Life Span. <i>Cell</i> , 2007, 128, 1173-1186.	28.9	910
40	The immunophenotype of acute myeloid leukemia: is there a relationship with prognosis?. <i>Blood Reviews</i> , 2006, 20, 71-82.	5.7	48
41	The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. <i>Cancer Cell</i> , 2006, 10, 389-399.	16.8	1,149